MD, PhD  

Kim A Papp

, Canada


Presentations

Sustained High Efficacy and a Favorable Safety Profile in Hard-to-Treat Areas in Patients with Moderate-to-Severe Psoriasis: Five-Year Results from a Phase 3 Trial 09 October 2019 00:00 - 00:00

Abstracts

Sustained High Efficacy and a Favorable Safety Profile in Hard-to-Treat Areas in Patients with Moderate-to-Severe Psoriasis: Five-Year Results from a Phase 3 Trial Psoriasis More